Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Linda Brower

Physician Assistant, Medical Elizabeth City, NC Physician Assistant

NPI 1083695787 CMS profile 10821715

1141 N Road St, Suite G, Elizabeth City, NC 27909

Open in the dashboard

General payments

$11,599

557 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Linda Brower of Elizabeth City, NC is reported in the CMS Open Payments database as having received $11,599 across 557 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,450 69
2024 General $1,759 99
2023 General $1,914 102
2022 General $3,426 116
2021 General $3,049 171

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Linda Brower
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Linda Brower were reported at $1,450. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Linda Brower Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,049 $156 $41–$563 $132
2022 $3,426 $185 $55–$649 $149
2023 $1,914 $199 $58–$717 $160
2024 $1,759 $206 $62–$740 $164
2025 $1,450 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Mannkind Corporation $2,141 50 payments
  2. Abbott Laboratories $1,900 95 payments
  3. Lilly USA, LLC $972 72 payments
  4. Novo Nordisk Inc $813 66 payments
  5. Corcept Therapeutics $500 21 payments
  6. AbbVie, Inc. $463 29 payments
  7. Insulet Corporation $419 13 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $383 16 payments
  9. Dexcom, Inc. $351 14 payments
  10. Esperion Therapeutics, Inc. $336 18 payments
  11. Other $3,320 163 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,207 551 payments
  2. Travel and Lodging $758 3 payments
  3. Consulting Fee $597 1 payment
  4. Education $37 2 payments
Products named General payments · program years 2021–2025
  1. AFREZZA $2,141 50 payments
  2. FreeStyle Libre 3 $1,431 72 payments
  3. Korlym $500 21 payments
  4. RYBELSUS $498 38 payments
  5. Omnipod $419 13 payments
  6. MOUNJARO $408 30 payments
  7. FreeStyle Libre 2 $379 19 payments
  8. Ozempic $367 37 payments
  9. JARDIANCE $349 14 payments
  10. NEXLETOL $336 18 payments
  11. Other $6,095 331 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

1,911

Median for Physician Assistant: 241

Drug cost

$1,026,659

Median for Physician Assistant: $4,110

Branded share of claims

75.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 224 $247,515
Mounjaro Tirzepatide Brand 173 $182,464
Jardiance Empagliflozin Brand 139 $109,832
Rybelsus Semaglutide Brand 69 $103,682
Tresiba Flextouch U-200 Insulin Degludec Brand 33 $52,360
Farxiga Dapagliflozin Propanediol Brand 50 $47,340
Tresiba Flextouch U-100 Insulin Degludec Brand 58 $40,830
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 43 $38,842
Trulicity Dulaglutide Brand 34 $35,436
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 27 $27,746

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYOSTED
  • Antares Pharma, Inc. $137
$137 — —
Korlym
  • Corcept Therapeutics $123
$123 — —
MOUNJARO
  • Lilly USA, LLC $99
$99 173 —
TEPEZZA
  • Amgen Inc. $75
$75 — —
SYNTHROID
  • AbbVie, Inc. $63
$63 125 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

557 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record